Marker Therapeutics, Inc.
0.9703-0.04 (-3.93%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · MRKR · USD
Key Stats
Market Cap
12.55MP/E (TTM)
-Basic EPS (TTM)
-1.35Dividend Yield
0%Recent Filings
8-K
First OTS patient treated safely
Marker Therapeutics kicked off its Off-the-Shelf MAR-T cell program by treating the first patient in the Phase 1 RAPID study on October 6, 2025, targeting AML and MDS with MT-401-OTS at an initial dose of 100x10^6 cells. The therapy proved well tolerated, mirroring the safety seen in prior MAR-T trials, while non-dilutive funding from FDA, NIH, and CPRIT fuels the effort without draining the company's runway. First patient treated. This off-the-shelf approach slashes manufacturing time to as little as 72 hours, boosting accessibility for aggressive cancers.
8-K
MT-601 shows strong lymphoma responses
Marker Therapeutics unveiled Phase 1 APOLLO study results for MT-601 in relapsed lymphoma patients, reporting a 66% objective response rate and 50% complete responses in 12 non-Hodgkin lymphoma cases, with 78% responses in nine Hodgkin cases. No dose-limiting toxicities or ICANS emerged across doses up to 400x10^6 cells, underscoring MT-601's clean safety profile in heavily pretreated patients. Dose expansion in DLBCL starts June 17, 2025. Cash lasts to Q2 2026.
10-Q
Q2 FY2025 results
Marker Therapeutics posted Q2 grant revenue of $0.9M, down 26% y/y but up from Q1's $0.3M (derived), amid ramped R&D spending on MT-601 lymphoma trials that drove an operating loss of $4.3M, 85% wider y/y, and net loss of $4.0M or $0.29/share on 14M diluted shares. YTD, revenue fell 50% to $1.2M while expenses climbed 39% to $10.1M, yielding a $8.5M net loss or $0.67/share; EPS aligns with shares outstanding, no anti-dilution flagged. Cash burned $7.4M in operations, leaving $10.5M in working capital and $11.8M total liquidity, bolstered by $4.5M post-quarter ATM raise—enough into Q2 2026. Yet regulatory hurdles in immuno-oncology trials loom large.
8-K
Auditor switch completed
Marker Therapeutics switched auditors on August 6, 2025, as Marcum LLP resigned following its acquisition by CBIZ CPAs, which was promptly engaged for the year ending December 31, 2025, starting with the Q2 review. No disagreements or reportable events marred the transition, though Marcum's prior reports flagged going concern doubts. Continuity holds firm. This ensures seamless financial oversight amid biotech pressures.
8-K
Marker partners for MT-601 manufacturing
Marker Therapeutics inked a statement of work with Cellipont Bioservices on June 16, 2025, for technology transfer and cGMP manufacturing of its lead MAR-T cell therapy, MT-601, to scale production for the ongoing Phase 1 APOLLO study in relapsed lymphoma patients. This partnership accelerates clinical supply while building toward a potential pivotal trial in diffuse large B-cell lymphoma. The collaboration leverages Cellipont's Texas facility for mid-to-late-stage development. Yet risks like clinical uncertainties persist.
IPO
Employees
Sector
Industry
BCTX
BriaCell Therapeutics Corp.
12.44-0.90
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
FATE
Fate Therapeutics, Inc.
1.34-0.15
IMRX
Immuneering Corporation
6.25-0.24
IMTX
Immatics N.V.
10.34-0.02
LRMR
Larimar Therapeutics, Inc.
4.31-0.04
MAIA
MAIA Biotechnology, Inc.
1.30-0.10
MRSN
Mersana Therapeutics, Inc.
9.56-0.67
TCRX
TScan Therapeutics, Inc.
1.92-0.21
TNGX
Tango Therapeutics, Inc.
7.83+0.04